HHC
AMRI

Hutchin Hill Capital’s Albany Molecular Research Inc AMRI Stock Holding History

Hutchin Hill Capital’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-32,300
Closed -$453K – 1190
2017
Q1 		$453K Buy
+32,300
New +$529K 0.01% 700
2013
Q3 		– Sell
-69,700
Closed -$827K – 642
2013
Q2 		$827K Buy
+69,700
New +$755K 0.09% 184

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Hutchin Hill Capital's AMRI Position: Q2 2017 in Review

Hutchin Hill Capital sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 32,300 shares — an estimated $453K sold.

Hutchin Hill Capital first reported a position in AMRI in Q2 2013 and held it in 2 quarters. The position peaked at $827K in Q2 2013. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

  • Hutchin Hill Capital reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 32,300 Albany Molecular Research Inc shares in Q2 2017, an estimated $453K.
  • Hutchin Hill Capital first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 2 quarters.
  • Hutchin Hill Capital's Albany Molecular Research Inc position peaked at $827K in Q2 2013.
  • 136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Hutchin Hill Capital's 13F filing for Q2 2017, filed 14 Aug 2017.